A Study of CS1003 in Subjects With Advanced Solid Tumors

In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.

CS1003 to be intravenously administered at the dose level determined during the dose escalation part

Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle